PDLLA Poly(DL-lactide) CAS 51056-13-9

CAS: 51056-13-9
Pureza: 99%
Molecular Formula：(C6H8O4)n
Peso Molecular: 0
EINECS: N/A
Storage Period: 1 years

Synonyms：PDLLA，Poly(DL-lactide)，Poly（DL-lactic acid），DL-polylactide

What is PDLLA Poly(DL-lactide) CAS 51056-13-9？

PDLLA CAS 51056-13-9 is an amorphous polymer with a glass transition temperature of 50-60℃ and a viscosity range of 0.2-7.0dl/g. The material has been approved by the FDA and can be used as an adjuvant for medical surgical anti-adhesive mucosa, microcapsules, microspheres and implants for sustained release, and can also be used as porous scaffolds for tissue engineering cell culture and bone fixation or tissue repair materials, such as surgical sutures, implants, artificial skin, artificial blood vessels, and ophthalmic retinas.

Especificação

Item	Resultado
Viscosidade intrínseca	0.2-7.0dl/g (0.1% g/mL, chloroform, 25°C)
Viscosity average molecular weight	5000-70w
Glass transition temperature	50-60°C
Solvente Residual	≤70ppm
Residual water	≤0.5%

Aplicação

‌1. Medical cosmetology‌: PDLLA is widely used as a facial filler in the field of medical cosmetology due to its excellent biocompatibility and degradability. It can stimulate the production of skin collagen, thereby improving skin sagging, wrinkles and depressions.
‌2. Medical devices‌: PDLLA is also widely used in the field of medical devices, such as drug-loaded coatings for degradable coronary stents, surgical sutures, hemostatic clips, etc. Its good biocompatibility and degradability make these medical devices safer and more effective during use.
‌3. Tissue engineering‌: PDLLA also has important applications in the field of tissue engineering, such as bone fixation and bone repair materials, tissue engineering scaffolds, etc. Its porous structure is conducive to the attachment and growth of cells, thereby promoting tissue repair and regeneration.
4‌. Drug controlled release‌: PDLLA can also be used for drug controlled release and sustained release packaging. By combining it with drugs to make dosage forms such as microspheres or microcapsules, the slow release and sustained action of drugs can be achieved, thereby improving the efficacy and safety of drugs. ‌
5. Degradation performance of PDLLA‌: PDLLA degrades relatively slowly, which enables it to provide longer-lasting therapeutic effects in clinical applications. Its degradation product is lactic acid, which is eventually metabolized into carbon dioxide and water, and is non-toxic and harmless to the human body‌.